Empagliflozin add‐on therapy is superior to metformin monotherapy in diabetic patients with NAFLD: An open‐label, single‐center, pilot clinical trial
The EMPA add-on therapeutic schedule in uncontrolled T2DM patients with NAFLD significantly ameliorated steatosis stages, liver function, anthropometric features, and biochemical parameters.
Authors
- Ayda Esmaeili (ORCID: https://orcid.org/0000-0001-9264-0248)
- Mohammadreza Mohammad Hosseiniazar
- Laya Hooshmand Gharabagh (ORCID: https://orcid.org/0000-0002-9401-4598)
- R Azar
Institutions
- Imam Khomeini Hospital (IR)
- Urmia University (IR)
- Urmia University of Medical Sciences (IR)
Publication Details
- Journal
- Journal of General and Family Medicine
- Published
- 2024-09-08
- DOI
- https://doi.org/10.1002/jgf2.723
- Citations
- 5
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.93